Literature DB >> 24761381

Simultaneous hepatosplenic T-cell lymphoma and myelofibrosis.

Ali M Gabali1, Tarek Jazaerly2, Chung-Che Jeff Chang3, Ronald Cleveland4, Lawrence Kass4.   

Abstract

Hepatosplenic T-cell lymphoma (HSTL) is a rare T-cell neoplasm of the lymphoid system. This type of lymphoma is characterized by sinusoidal infiltration of spleen, liver, bone marrow and lymph nodes by neoplastic lymphocytes. Here, we discuss a patient who had a left axillary lymph node biopsy with characteristic histological and immunohistochemical features of HSTL. In addition, infiltrating neoplastic T-cells and simultaneous characteristic features of myelofibrosis (MF) were also present in the bone marrow biopsy specimen. In contrast to secondary MF, primary MF is a progressive disease and may significantly affect the prognosis of coexisting HSTL. There are few reports in the literature talking about mild bone marrow fibrosis in association with T cell lymphoma, however marked increase in bone marrow fibrosis and HSTL never being reported. This case is shedding light on HSTL and marked increase in bone marrow fibrosis.

Entities:  

Keywords:  Bone marrow; CD3; Jak2; T-cell; liver

Year:  2014        PMID: 24761381      PMCID: PMC3994706          DOI: 10.4103/2231-0770.130343

Source DB:  PubMed          Journal:  Avicenna J Med        ISSN: 2231-0770


INTRODUCTION

Hepatosplenic T cell lymphoma is a rare and unique entity of peripheral T cell lymphoma that is characterized sinusoidal infiltration of liver, spleen and bone marrow by neoplastic cells. It affects young male individuals in most cases with an aggressive clinical course and a median survival rate of less than 2 year. The relationship between bone marrow fibrosis and lymphoma has been a subject of controversy and there are few reports in the literature talking about mild bone marrow fibrosis in association with T cell lymphoma. This case is shedding light on HSTL and marked increase in bone marrow fibrosis.

CASE REPORT

This was a case of a 37-year-old male patient who was admitted to the hospital because of a right sided abdominal mass. On examination, he had left axillary lymphadenopathy (1 cm) and hepatosplenomegaly. The complete blood count showed mild anemia and severe thrombocytopenia [Table 1]. The peripheral blood smear showed intermediate-sized atypical lymphocytes, immature granulocytes, nucleated red blood cells and tear-drop cells [Figure 1a]. Liver function tests were mildly impaired and screening for auto-antibody as well as viral serology for hepatitis A, B and C were negative. Computed tomography (CT) scan of the abdomen showed massive hepatosplenomegaly and minimal lymphadenopathy. He underwent left axillary lymph node biopsy followed 1 week later by bone marrow biopsy.
Table 1

Initial patient's CBC value

Figure 1

(a) Tear-drop red blood cell, original magnification ×100. (b) H and E stains of bone marrow biopsy specimen showing increased cellularity and atypical megakaryocytes with both large and small darkly stained nuclei, original magnification ×40

Initial patient's CBC value (a) Tear-drop red blood cell, original magnification ×100. (b) H and E stains of bone marrow biopsy specimen showing increased cellularity and atypical megakaryocytes with both large and small darkly stained nuclei, original magnification ×40 The patient was given two cycles of high dose dexamethasone, cytarabine and cisplatine followed by hyper-fractionated cyclophosphamide, doxorubicin, vincristine and dexamethasone chemotherapy regimen. There was an initial dramatic reduction in the size of spleen and liver which were confirmed by abdominal CT scan. However, 2 months later the spleen increased in size and he developed severe thrombocytopenia. At 5 months after completing radiotherapy for his enlarging spleen, the patient died of complications of septicemia. No post-mortem study was done on the patient.

RESULTS

The bone marrow biopsy showed increased cellularity and clusters of atypical megakaryocytes showing darkly stained and hypolobated nuclei [Figure 1b]. Cells of the neutrophilic granulocytic series showed normal maturation up to the metamyelocyte stage. Anti-CD34 staining of bone marrow showed marked intrasinusoidal hematopoiesis and the reticulin stain showed substantially increased reticulin throughout the specimen. There were several instances of bone marrow sinusoidal infiltration by neoplastic cells [Figure 2a] that stained positively for the CD3 T-cell marker [Figure 2b inset]. Since it is important to differentiate between primary and secondary forms of this lesion, in the current case we used melting curve analysis of polymerase chain reaction (PCR) amplified sample from paraffin fixed tissue, as described previously.[1] No JAK2 mutation was amplified in lymph node or bone marrow specimens.
Figure 2

(a) Lymph node biopsy showing sinusoidal infiltration atypical lymphocytes. The infiltrating neoplastic cells are shown at higher magnification in the inset (b) H and E stains of bone marrow biopsy specimen showing sinusoidal infiltration of medium-sized atypical lymphocytes with irregular nuclei and a moderate amount of agranular cytoplasm that stain positive for anti-CD3 immunohistochemical stain (inset)

(a) Lymph node biopsy showing sinusoidal infiltration atypical lymphocytes. The infiltrating neoplastic cells are shown at higher magnification in the inset (b) H and E stains of bone marrow biopsy specimen showing sinusoidal infiltration of medium-sized atypical lymphocytes with irregular nuclei and a moderate amount of agranular cytoplasm that stain positive for anti-CD3 immunohistochemical stain (inset) Biopsy of the axillary lymph node revealed extensive sinusoidal infiltration by atypical lymphocytes [Figure 2b inset] with intact B- and paracortical T-zones [Figure 2b]. The cells were of T-cell cytotoxic lineage with positive CD3, CD57 and TIA1. Characteristically, the neoplastic cells were negative for CD5 expression. The differential diagnosis of this lesion included NK/T-cell lymphoma which was less likely as the neoplastic cells were negative for CD56 NK cell marker. Furthermore, the neoplastic cells were negative for both CD4 and CD8 and showed post-thymic maturation with the loss of CD1a and TdT expression. Genetic studies confirmed the presence of clonal rearrangement of the T-cell receptor delta gene. In addition, staining the neoplastic cells using a monoclonal antibody that binds to the TCR β-subunit (BF1) was negative. However, although beta and gamma T-cell receptor gene analysis is not done, both the clonal delta gene rearrangement and the negative anti-BF1 immunohistochemical stain support the γδ subtype of this lesion. Furthermore, flow cytometric analysis of the lymph node specimen demonstrated the presence of an abnormal T-cell population expressing CD3 and CD2 with CD5 deletion and low expression of CD7, CD4 and CD8.

DISCUSSION

Hepatosplenic T-cell lymphoma (HSTL) represents approxi-mately less than 5% of all peripheral T-cell lymphomas.[2] Histologically, the disease is characterized by T-cell neoplastic infiltration of the liver, spleen, bone marrow and lymph nodes.[3] In about 20% of the reported cases, mild peripheral lymphadenopathy was also present.[2] Liver biopsy was not performed in this case because of concern that the patient might bleed excessively due to thrombocytopenia. The clinical presentation of hepatosplenomegaly as well as the histological findings in bone marrow and lymph node specimen, including sinusoidal infiltration by neoplastic cytotoxic T-cell lineage that characteristically has CD5 deletion, are consistent with HSTL.[345] Furthermore, the initial regression of his hepatosplenomegaly after chemotherapy also supports the diagnosis of HSTL. The bone marrow findings of increased reticulin, along with increased numbers of atypical appearing megakaryocytes, metamyelocyte/band stage and intrasinusoidal hematopoiesis support the coexistence of myelofibrosis (MF), which may significantly affect the prognosis of coexisting HSTL. The morphologic findings in the bone marrow as well as the clinical presentation of splenomegaly warrants a molecular testing for JAK2 mutation. Here we used melting curve analysis of PCR amplified sample from paraffin fixed lymph node and bone marrow tissues.[167] The results of JAK2 analysis in our case did not allow us to reach a final unequivocal decision since JAK2 mutation was not amplified. Thus, we could not exclude the diagnosis of primary MF since JAK2 mutation is only positive in 50% of the reported cases of primary MF.[89] However, considering the clinical presentation and the histological findings of both lymph node and bone marrow, secondary rather than Primary MF is more likely to be present in our case. Until date, no study has shown primary MF occurring simultaneously with HSTL and few reports have discussed the subsequent development of secondary MF in the background of peripheral T-cell lymphoma.[10] Our case illustrates that HSTL and MF can occur simultaneously at the time of diagnosis.

CONCLUSIONS

HSTL with concomitant MF presents a challenge for clinical and pathologic diagnosis. The diagnostic and prognostic significance of the coexistence of the two diseases is important and we should be aware of these two different disease entities in an individual patient.
  10 in total

1.  Hepatosplenic T-cell lymphoma.

Authors:  V Franco; A M Florena
Journal:  Br J Haematol       Date:  2001-07       Impact factor: 6.998

2.  Hepatosplenic T-cell lymphoma of alphabeta lineage.

Authors:  S Kumar; C Lawlor; E S Jaffe
Journal:  Am J Surg Pathol       Date:  2001-07       Impact factor: 6.394

Review 3.  Chronic idiopathic myelofibrosis: clinicopathologic features, pathogenesis, and prognosis.

Authors:  Arsalan Ahmed; Chung-Che Jeff Chang
Journal:  Arch Pathol Lab Med       Date:  2006-08       Impact factor: 5.534

4.  Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system.

Authors:  Randall J Olsen; Zhouwen Tang; Daniel H Farkas; David W Bernard; Youli Zu; Chung-Che Chang
Journal:  Arch Pathol Lab Med       Date:  2006-07       Impact factor: 5.534

5.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

6.  Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas.

Authors:  W R Macon; N B Levy; P J Kurtin; K E Salhany; M Y Elkhalifa; T T Casey; F E Craig; C L Vnencak-Jones; M L Gulley; J P Park; J B Cousar
Journal:  Am J Surg Pathol       Date:  2001-03       Impact factor: 6.394

7.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

Review 8.  Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990.

Authors:  E Weidmann
Journal:  Leukemia       Date:  2000-06       Impact factor: 11.528

9.  T cell lymphoma associated with myelofibrosis.

Authors:  Sujatha A Rao; Susan R S Gottesman; Min C Nguyen; Albert S Braverman
Journal:  Leuk Lymphoma       Date:  2003-04

Review 10.  Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.

Authors:  Karim Belhadj; Felix Reyes; Jean-Pierre Farcet; Herve Tilly; Christian Bastard; Regis Angonin; Eric Deconinck; Frederic Charlotte; Veronique Leblond; Eric Labouyrie; Pierre Lederlin; Jean-Francois Emile; Beatrice Delmas-Marsalet; Bertrand Arnulf; Elie-Serge Zafrani; Philippe Gaulard
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113

  10 in total
  2 in total

1.  Hodgkin's lymphoma associated with myelofibrosis: A case report.

Authors:  Rong Fu; Hong Yu; Yu-Hong Wu; Hui Liu; Zong-Hong Shao
Journal:  Oncol Lett       Date:  2015-06-30       Impact factor: 2.967

2.  Intravascular large B-cell lymphoma associated with myelofibrosis: A case report.

Authors:  Jong Gwon Choi; Hwan Hwi Cho; Sang Rok Kang; Se Min Jang; Eun Hyung Yoo; Hyun Jung Cho; Sun Moon Kim; Do Yeun Cho
Journal:  Mol Clin Oncol       Date:  2017-08-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.